Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5-HT5 receptors.

D L Nelson1

  • 1Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285-0814, USA. dlgnelson@lilly.com

Current Drug Targets. CNS and Neurological Disorders
|February 18, 2004
PubMed
Summary
This summary is machine-generated.

The 5-HT(5) receptor family, including 5-HT(5A) and 5-HT(5B), is primarily in the CNS. The 5-HT(5A) receptor knockout mice show reduced responses to LSD, highlighting its role.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of a new schistosomicidal agent 2-[(methylpropyl)amino]-1-octanethiosulfuric acid against an oxamniquine resistant Schistosoma mansoni isolate.

Memorias do Instituto Oswaldo Cruz·1999
Same author

Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying 'null' mutations.

Gene therapy·1999
Same author

Alternative splicing in the murine and human FXR1 genes.

Genomics·1999
Same author

The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation.

Blood·1999
Same author

Cue set size effects: sampling activated associates or cross-target interference?

Memory & cognition·1999
Same author

Development of fluorine-18-labeled 5-HT1A antagonists.

Journal of medicinal chemistry·1999
Same journal

Partial QSAR analysis of some selected natural inhibitors of FAAH suggests a working hypothesis for the development of endocannabinoid-based drugs.

Current drug targets. CNS and neurological disorders·2005
Same journal

Therapeutic perspectives of inhibitors of endocannabinoid degradation.

Current drug targets. CNS and neurological disorders·2005
Same journal

Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors.

Current drug targets. CNS and neurological disorders·2005
Same journal

Cannabinoids: between neuroprotection and neurotoxicity.

Current drug targets. CNS and neurological disorders·2005
Same journal

From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.

Current drug targets. CNS and neurological disorders·2005
Same journal

Endocannabinoids in neuroimmunology and stress.

Current drug targets. CNS and neurological disorders·2005
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • The serotonin 5-HT(5) receptor family comprises two subtypes: 5-HT(5A) and 5-HT(5B).
  • 5-HT(5A) receptors are found in humans, mice, and rats, primarily in the central nervous system (CNS), with some presence in the carotid body.
  • 5-HT(5B) receptors are expressed in rodents but absent in humans due to coding sequence interruptions.

Purpose of the Study:

  • To review the current understanding of the 5-HT(5) receptor family.
  • To highlight the limited pharmacological characterization and known functions of these receptors.

Main Methods:

  • Literature review of studies on 5-HT(5A) and 5-HT(5B) receptor distribution and function.
  • Analysis of pharmacological data, including radioligand binding assays using [(125)I]LSD and [(5)H]5-CT.

Related Experiment Videos

  • Examination of findings from 5-HT(5A) receptor knockout mouse models.

    • Main Results:

    • 5-HT(5A) receptors exhibit a broad CNS distribution, while 5-HT(5B) receptors have a restricted distribution.
    • 5-HT(5A) receptors couple to Gi/o proteins, inhibiting adenylyl cyclase activity.
    • LSD shows high affinity for both receptor subtypes, acting as a partial agonist at 5-HT(5A); 5-carboxamidotryptamine (5-CT) also demonstrates high affinity and potency at 5-HT(5A).

    Conclusions:

    • The 5-HT(5A) receptor knockout mice display a blunted locomotor response to LSD.
    • The in vivo role of the 5-HT(5B) receptor remains largely unknown.
    • 5-HT(5) receptors represent some of the least understood serotonin receptor subtypes.